Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for persona...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez de Castro, D, Clarke, P A, Al-Lazikani, B, Workman, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577635/
https://www.ncbi.nlm.nih.gov/pubmed/23361103
http://dx.doi.org/10.1038/clpt.2012.237
_version_ 1782259935513411584
author Gonzalez de Castro, D
Clarke, P A
Al-Lazikani, B
Workman, P
author_facet Gonzalez de Castro, D
Clarke, P A
Al-Lazikani, B
Workman, P
author_sort Gonzalez de Castro, D
collection PubMed
description The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for personalized cancer medicine. We also highlight resistance mechanisms for epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer. We envisage a future requiring the use of longitudinal genome sequencing and other omics technologies alongside combinatorial treatment to overcome cellular and molecular heterogeneity and prevent resistance caused by clonal evolution.
format Online
Article
Text
id pubmed-3577635
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35776352013-03-01 Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance Gonzalez de Castro, D Clarke, P A Al-Lazikani, B Workman, P Clin Pharmacol Ther Review The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for personalized cancer medicine. We also highlight resistance mechanisms for epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer. We envisage a future requiring the use of longitudinal genome sequencing and other omics technologies alongside combinatorial treatment to overcome cellular and molecular heterogeneity and prevent resistance caused by clonal evolution. Nature Publishing Group 2013-03 2013-01-30 /pmc/articles/PMC3577635/ /pubmed/23361103 http://dx.doi.org/10.1038/clpt.2012.237 Text en Copyright © 2013 American Society of Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Review
Gonzalez de Castro, D
Clarke, P A
Al-Lazikani, B
Workman, P
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
title Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
title_full Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
title_fullStr Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
title_full_unstemmed Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
title_short Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
title_sort personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577635/
https://www.ncbi.nlm.nih.gov/pubmed/23361103
http://dx.doi.org/10.1038/clpt.2012.237
work_keys_str_mv AT gonzalezdecastrod personalizedcancermedicinemoleculardiagnosticspredictivebiomarkersanddrugresistance
AT clarkepa personalizedcancermedicinemoleculardiagnosticspredictivebiomarkersanddrugresistance
AT allazikanib personalizedcancermedicinemoleculardiagnosticspredictivebiomarkersanddrugresistance
AT workmanp personalizedcancermedicinemoleculardiagnosticspredictivebiomarkersanddrugresistance

Ejemplares similares